Tmunity to Present at the 39th Annual J.P. Morgan Healthcare Conference
A live webcast of the presentation will be available on the “Events and Presentations” page of the Tmunity website at https://www.tmunity.com/events. Tmunity will maintain an archived replay of the webcast on the website for 30 days after the conference.
About Tmunity Therapeutics
Tmunity is a private, clinical-stage biotherapeutics company, focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn), with groundbreaking scientific, clinical and manufacturing expertise, and the demonstrated track record of its founders (Carl June, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T-cell medicine. Through Penn, the Parker Institute for Cancer Immunotherapy and other collaborations, Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T-cell activation and direction in the body, with a focus in cancer and two programs currently in clinic development.
With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn, and its own dedicated cGMP manufacturing facility in East Norriton, PA, to pursue process improvement and production scale-up in support of clinical development of its T-cell therapies. For more information, visit www.tmunity.com and connect with us on social media at @TmunityTx and LinkedIn.
Stern Investor Relations
Source: Tmunity Therapeutics, Inc.